A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2016
At a glance
- Drugs AZD 5718 (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 20 Oct 2016 Status changed from active, no longer recruiting to completed.
- 16 Aug 2016 Status changed from recruiting to active, no longer recruiting.